Anne Derache
University of Paris
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Anne Derache.
Antimicrobial Agents and Chemotherapy | 2010
Almoustapha Issiaka Maiga; Diane Descamps; Laurence Morand-Joubert; Isabelle Malet; Anne Derache; Mamadou Cisse; Victoria Koita; Alain Akonde; Bah Diarra; Marc Wirden; Anatole Tounkara; Yvan Verlinden; Christine Katlama; Dominique Costagliola; Bernard Masquelier; Vincent Calvez; Anne-Geneviève Marcelin
ABSTRACT Susceptibility to etravirine (ETR), an expanded-spectrum nonnucleoside reverse transcriptase inhibitor (NNRTI), is dependent on the type and number of NNRTI resistance-associated mutations (RAMs). Studies have shown that some HIV-1 subtypes may have natural polymorphisms described as ETR RAMs. This study addresses the prevalence of ETR RAMs in treatment-naïve patients infected with HIV-1 non-B subtypes and its potential impact on ETR susceptibility. The prevalence of ETR RAMs in 726 antiretroviral-naïve patients infected with non-B HIV-1 subtypes was studied. ETR genotypic resistance was interpreted according to Agence Nationale de Recherches sur le SIDA and Stanford algorithms. NNRTI phenotypic susceptibilities of samples with at least one ETR RAM were measured. Overall, 75 (10.3%) of 726 sequences harbored at least one ETR RAM: sequences from 72 patients (10%) each had one ETR RAM, and sequences from 3 patients (0.4%) each had two ETR RAMs (V90I and Y181C in one case and V90I and A98G in two cases). None of the viruses had three or more ETR RAMs, and none were consequently classified as resistant to ETR. All sequences with two ETR RAMs belonged to subtype CRF02_AG. The presence of one ETR RAM was statistically more frequent in subtype CRF02_AG than in other non-B subtypes (P = 0.004). Three new mutation profiles (E138A and V179I, Y181C and H221Y, and V90I and Y181C) showing decreased ETR phenotypic susceptibility were identified. In conclusion, although the prevalence of ETR RAMs in treatment-naïve patients infected with non-B HIV-1 subtypes was 10%, in most cases this had no significant impact on ETR susceptibility. However, the transmission of drug-resistant viruses with Y181C in a non-B genetic background has a potential for impact on ETR susceptibility.
Journal of Antimicrobial Chemotherapy | 2008
Anne Derache; Almoustapha-Issiaka Maiga; Ousmane Traore; Alain Akonde; Mamadou Cisse; Bernard Jarrousse; Victoria Koita; Bah Diarra; Guislaine Carcelain; Francis Barin; Cecilia Pizzocolo; Louis Pizarro; Christine Katlama; Vincent Calvez; Anne-Geneviève Marcelin
OBJECTIVES To describe HIV-1 variants circulating in Mali and to estimate the rate of transmission of HIV-1 drug resistance in 2006. PATIENTS AND METHODS Viral reverse transcriptase (RT) and protease (PR) genes from 198 antiretroviral (ARV)-naive patients diagnosed HIV-1 positive in May 2006 in Bamako and Segou were sequenced. RESULTS Although CRF02_AG was always the predominant HIV-1 subtype observed (72%), a higher genetic diversity than that in 2005 was observed. The overall prevalence of primary resistance is 11.5% in Mali in 2006, according to the 2007 IAS-USA list of mutations [nucleoside RT inhibitor (NRTI): 1.5%, non-NRTI (NNRTI): 9% and PI: 1%], and 2.5% (NRTI: 1%, NNRTI: 1.5% and PI: 0%), according to the Stanford list of mutations. There was no significant difference between 2005 and 2006 in the overall primary resistance prevalence or in the prevalence of mutations in the different ARV classes. Resistance mutations found in RT and PR genes are in agreement with the highly active antiretroviral therapy regimen available in Mali, except for V90I, V106I and A98G mutations which are associated with etravirine resistance, but polymorphic in non-B subtypes. CONCLUSIONS HIV-1 genetic diversity seems increased in Mali, but the overall HIV-1 primary resistance prevalence remains low. This is consistent with the findings from other West African countries where prevalence rates are lower than 5%. However, considering the large scaling up of ARV use in this country, it is necessary to regularly monitor the development of primary resistance in Mali.
AIDS | 2007
Anne-Geneviève Marcelin; Bernard Jarrousse; Anne Derache; Madina Ba; Marie-léa Dakouo; Alioune Doumbia; Ibrahima Haidara; Almoustapha Issiaka Maiga; Guislaine Carcelain; Gilles Peytavin; Christine Katlama; Vincent Calvez
Early failures to stavudine/lamivudine/nevirapine used as a generic fixed-dose combination in Mali showed resistance mutations in 50% of cases (mostly M184V and Y181C). No thymidine analogue mutations were seen, suggesting that most nucleoside reverse transcriptase inhibitors could be used in a second-line regimen. This highlights the importance of the accessibility of HIV-RNA assays for monitoring treated patients in resource-poor countries to detect early virological failure in order to preserve future therapeutic options.
AIDS | 2007
Isabelle Malet; Marc Wirden; Anne Derache; Anne Simon; Christine Katlama; Vincent Calvez; Anne-Geneviève Marcelin
Sequences from 82 protease inhibitors (PI)-experienced patients were analysed for the presence of previously described in-vitro resistance mutations to PA-457 located in the C-terminal capside (H226Y, L231F, L231M) and in the N-terminal SP1 (A1V, A3T, A3V) within the CA-SP1 boundary domain. Overall, the CA-SP1 cleavage site was highly conserved in PI pre-treated patients and only one patient showed an L231M mutation. The impact of this mutation should be further addressed in vivo.
Journal of Medical Virology | 2008
Isabelle Malet; Cathia Soulié; Luba Tchertanov; Anne Derache; Bahia Amellal; Ousmane Traore; Anne Simon; Christine Katlama; Jean-François Mouscadet; Vincent Calvez; Anne-Geneviève Marcelin
HIV‐1 integrase is one of the three essential enzyme required for viral replication and has a great potential as a novel target for anti‐HIV drugs. The sequence variability of the entire integrase (IN) was examined in HIV‐1 subtype B and CRF02‐AG antiretroviral naïve infected patients for the presence of naturally occurring polymorphisms IN gene sequences and protein structures from both subtypes were compared. The phylogenetic analysis showed a total concordance between the 3 pol gene sequences for patients identified as subtype B whereas 3% of patients identified as CRF02‐AG showed a mixture of subtypes. The analysis of IN aa sequences showed that 13 positions (K/R14, V/I31, L/I101, T/V112, T/A124, T/A125, G/N134, I/V135, K/T136, V/I201, T/S206, L/I234, and S/G283) differed between subtypes B and CRF02‐AG. As observed in the 3D model of the preintegration complex, these differences may impact the functional property of IN. The fact that most variations were grouped suggests that some of them are linked together through compensatory mechanisms. This comparison allowed us to identify several variations of amino acids in HIV‐1 IN subtype CRF02‐AG that could have a putative impact on anti‐integrase sensitivity. In particular, the region formed by Thr125, Thr124, Val31 contains at least one residue, T125, which variation has been involved in eliciting resistance to the naphtyridine carboxamide L870,810 IN inhibitor. In conclusion, virological response to anti‐integrase should be studied carefully, according to the subtype, in clinical trials. J. Med. Virol. 80:754–761, 2008.
AIDS | 2005
Marc Wirden; Isabelle Malet; Anne Derache; Marcelin Ag; Bénédicte Roquebert; Anne Simon; Myriam Kirstetter; Laurence Morand Joubert; Christine Katlama; Vincent Calvez
We analysed the quasispecies at a clonal level in patients whose plasma genotypic test harboured K65R with L74V or thymidine analogue mutations (TAM). We showed that the K65R and TAM such as M41L, D67N, T215Y/D, L210W and K219E can be borne by the same virus. We found no clone bearing both K65R and L74V substitutions. Moreover, the S68G and V75I mutations are not necessarily linked with K65R, and could thus have their own resistance effect.
The Lancet HIV | 2017
Collins Iwuji; Joanna Orne-Gliemann; Joseph Larmarange; Eric Balestre; Rodolphe Thiébaut; Frank Tanser; Nonhlanhla Okesola; Thembisa Makowa; Jaco Dreyer; Kobus Herbst; Nuala McGrath; Till Bärnighausen; Sylvie Boyer; Tulio de Oliveira; Claire Rekacewicz; Brigitte Bazin; Marie-Louise Newell; Deenan Pillay; François Dabis; C. Iwuji; Kevi Naidu; Tamsen Rochat; Johannes Viljoen; Thembelihle Zuma; Sophie Karcher; Mélanie Plazy; Mélanie Prague; Thierry Tiendrebeogo; Hermann Donfouet; Andréa Gosset
BACKGROUND Universal antiretroviral therapy (ART), as per the 2015 WHO recommendations, might reduce population HIV incidence. We investigated the effect of universal test and treat on HIV acquisition at population level in a high prevalence rural region of South Africa. METHODS We did a phase 4, open-label, cluster randomised trial of 22 communities in rural KwaZulu-Natal, South Africa. We included individuals residing in the communities who were aged 16 years or older. The clusters were composed of aggregated local areas (neighbourhoods) that had been identified in a previous study in the Hlabisa subdistrict. The study statisticians randomly assigned clusters (1:1) with MapInfo Pro (version 11.0) to either the control or intervention communities, stratified on the basis of antenatal HIV prevalence. We offered residents repeated rapid HIV testing during home-based visits every 6 months for about 4 years in four clusters, 3 years in six clusters, and 2 years in 12 clusters (58 cluster-years) and referred HIV-positive participants to trial clinics for ART (fixed-dose combination of tenofovir, emtricitabine, and efavirenz) regardless of CD4 cell count (intervention) or according to national guidelines (initially ≤350 cells per μL and <500 cells per μL from January, 2015; control). Participants and investigators were not masked to treatment allocation. We used dried blood spots once every 6 months provided by participants who were HIV negative at baseline to estimate the primary outcome of HIV incidence with cluster-adjusted Poisson generalised estimated equations in the intention-to-treat population after 58 cluster-years of follow-up. This study is registered with ClinicalTrials.gov, number NCT01509508, and the South African National Clinical Trials Register, number DOH-27-0512-3974. FINDINGS Between March 9, 2012, and June 30, 2016, we contacted 26 518 (93%) of 28 419 eligible individuals. Of 17 808 (67%) individuals with a first negative dried blood spot test, 14 223 (80%) had subsequent dried blood spot tests, of whom 503 seroconverted after follow-up of 22 891 person-years. Estimated HIV incidence was 2·11 per 100 person-years (95% CI 1·84-2·39) in the intervention group and 2·27 per 100 person-years (2·00-2·54) in the control group (adjusted hazard ratio 1·01, 95% CI 0·87-1·17; p=0·89). We documented one case of suicidal attempt in a woman following HIV seroconversion. 128 patients on ART had 189 life-threatening or grade 4 clinical events: 69 (4%) of 1652 in the control group and 59 (4%) of 1367 in the intervention group (p=0·83). INTERPRETATION The absence of a lowering of HIV incidence in universal test and treat clusters most likely resulted from poor linkage to care. Policy change to HIV universal test and treat without innovation to improve health access is unlikely to reduce HIV incidence. FUNDING ANRS, GiZ, and 3ie.
Antimicrobial Agents and Chemotherapy | 2006
Marc Wirden; Bénédicte Roquebert; Anne Derache; Anne Simon; Claudine Duvivier; Jade Ghosn; Stéphanie Dominguez; Véronique Boutonnet; Zaina Ait-Arkoub; Christine Katlama; Vincent Calvez; Anne-Geneviève Marcelin
ABSTRACT We analyzed 3,475 human immunodeficiency virus sequences and 241 therapeutic histories. The L74I mutation was carried by 7% of viruses. L74I was strongly associated with T215F, K70R, and V75M/S/T/A mutations and increased with the number of thymidine analog mutations. It seemed to be linked to the use of abacavir or efavirenz.
Clinical Infectious Diseases | 2017
Dami Collier; Collins Iwuji; Anne Derache; Tulio de Oliveira; Nonhlanhla Okesola; Alexandra Calmy; François Dabis; Deenan Pillay; Ravindra K. Gupta
Summary A community based, second-line treatment cohort of 102 subjects was followed monthly in community clinics with a total of 178 patient-years of follow-up; second-line virological failure was frequent in this setting.
Journal of Antimicrobial Chemotherapy | 2016
Josephine Brice; Mariam Sylla; Sophie Sayon; Fatoumata Telly; Djeneba Bocar-Fofana; Robert L. Murphy; Sidonie Lambert-Niclot; Eve Todesco; Maxime Grudé; Francis Barin; Souleymane Diallo; Deenan Pillay; Anne Derache; Vincent Calvez; Marcelin Ag; Almoustapha Issiaka Maiga
Background Absence of detectable viraemia after treatment cessation in some vertically HIV-infected (VHIV) children suggests that early initiation of HAART could lead to functional cure. Objectives We described the factors associated with HIV antibody levels and the viral reservoir size in HAART-treated VHIV children. Methods Study included 97 VHIV children with virological suppression, in Bamako, Mali. The anti-gp41 antibody activities and HIV serostatus were assessed. The viral reservoir size was measured by quantifying total cell-associated HIV DNA. Results Among the children studied, the median total HIV DNA level was 445 copies/10 6 cells (IQR = 187-914) and the median anti-gp41 antibody activity was 0.29 OD (IQR = 0.18-0.75). Low activity of anti-gp41 antibodies was associated with a younger age of HAART initiation ( P = 0.01). Overall, eight HIV-1 seroreversions were identified. Conclusions Study identified potential candidates with low viral reservoir and low antibody levels or activities for future trials aiming to reduce HIV-1 reservoir to limit HAART duration.